Towards the future of the treatment of heroin addiction. New challenges/issues to be addressed

Heroin Addiction and Related Clinical Problems

Volumn 17, Issue 4, 2015, Pages 5-8

  Maremmani, Icro ^a,b,c,d,e   Maremmani, Angelo Giovanni Icro ^a,b,d  

^a UNIVERSITY OF PISA   (Italy)

^b AU CNS   (Italy)

^c G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

^d EUROPAD European Opiate Addiction Treatment Association   (Italy)

^e WFTOD – World Federation for the Treatment of Opioid Dependence ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ILLICIT DRUG; METHADONE;

ALCOHOL ABUSE; ALCOHOLISM; ALGORITHM; ANXIETY DISORDER; COMORBIDITY; DETOXIFICATION; EDITORIAL; HEALTH CARE SYSTEM; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; IMPULSE CONTROL DISORDER; MOOD DISORDER; NEEDS ASSESSMENT; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUALITY OF LIFE; RISK REDUCTION; SYMPTOM;

EID: 84946894225     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (33)

1. Alho H., Auriacombe M., Fischer G., Maremmani I., Scherbaum N., Torrens M. (2013): Can outcomes monitoring of opioid maintenance treatment be improved in Europe? A statement by some European experts with interests in opioid maintenance treatment and its safety [Letter]. Heroin Addict Relat Clin Probl. 15(1): 63-64.
2. Alho H., Littlewood R., Maremmani I. (2014): Defining a new approach to measuring outcomes in opioid dependence management:. Heroin Addict Relat Clin Probl. 16(2): 11-16.
3. Berrocoso E., Sanchez-Blazquez P., Garzon J., Mico J. A. (2009): Opiates as antidepressants. Curr Pharm Des. 15(14): 1612-1622.
4. Colasanti A., Rabiner E. A., Lingford-Hughes A., Nutt D. J. (2011): Opioids and anxiety. J Psychopharmacol. 25(11): 1415-1433.
5. Deltito J., Maremmani I. (2001): The promise of opioid receptor antagonist drugs in the treatment of neuropsychiatric disorders. Heroin Addict Relat Clin Probl. 3(1): 7-12.
6. Dole V. P., Nyswander M. E. (1965): A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrocloride. JAMA. 193: 80-84.
7. Dole V. P., Nyswander M. E., Warner A. (1968): Successful treatment of 750 criminal addicts. JAMA. 206: 2708-2711.
8. Emrich H. M. (1984): Endorphins in psychiatry. Psychiatr Dev. 2(2): 97-114.
9. Gerra G., Maremmani I., Capovani B., Somaini L., Saenz E., Busse A., Kleber H. (2009): Long-acting opioid-agonists in the treatment of heroin addiction: why should we call them "substitution". Subst Use Misuse. 44(5): 663-671.
10. Gold M. S., Pottash A. L. C., Sweeney D. R., Martin D., Extein I. (1982): Antimanic, antidepressant, and antipanic effects of opiate: clinical, neuro-anatomical, and biochemical evidence. Ann NY Acad Sci. 398: 140-150.
11. Joseph H. (2006): In the Service of Patients: The Legacy of Dr. Dole. Heroin Addict Relat Clin Probl. 8(4): 9-28.
12. Lubrano S., Pacini M., Giuntoli G., Maremmani I. (2002): Is craving for heroin and alcohol related to low methadone dosages in methadone maintened patients. Heroin Addict Relat Clin Probl. 4(2): 11-17.
13. Maremmani A. G. I., Pani P. P., Rovai L., Bacciardi S., Rugani F., Dell’osso L., Pacini M., Maremmani I. (2013): The effects of agonist opioids on the psychopathology of opioid dependence. Heroin Addict Relat Clin Probl. 15(2): 47-56.
14. Maremmani A. G. I., Quaranta G., Bacciardi S., Rovai L., Rugani F., Pacini M., Nisita C., Maremmani I. (2014): Alcohol use disorder and past heroin addiction. A successfully treated ‘masked heroinism’ patient. Heroin Addict Relat Clin Probl. 16(2): 37-42.
15. Maremmani A. G. I., Rovai L., Pani P. P., Pacini M., Lamanna F., Rugani F., Schiavi E., Dell’osso L., Maremmani I. (2011): Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts? Ann Gen Psychiatry. 10:17.
16. Maremmani I., Barra M., Burton-Phillips E., Cecchini I., Di Chiara G., Gerra G., Mantovani L., Pani P. P., Pitts G., Rossi A., Somaini L., Starace F. (2013): The Italian Manifesto for the treatment of heroin addiction. The mixed care model. A proposed layout for a new healthcare system for citizens with heroin addiction. Heroin Addict Relat Clin Probl. 15(2): 63-78.
17. Maremmani I., Maremmani A. G. I., Lubrano S., Nardini R., Dell’osso L., Pacini M. (2014): Who are resistant patients? Quality of treatment and disease control. Addict Disord Their Treatment. 13(3): 116-124.
18. Maremmani I., Maremmani A. G. I., Rugani F., Rovai L., Pacini M., Bacciardi S., Deltito J., Dell’osso L., Akiskal H. S. (2012): Clinical presentations of substance abuse in bipolar heroin addicts at time of treatment entry. Ann Gen Psychiatry. 11(23).
19. Maremmani I., Pacini M. (2006): Combating the Stigma: Discarding the Label “Substitution Treatment” in Favour of “Behaviour-Normalization Treatment”. Heroin Addict Relat Clin Probl. 8(4): 5-8.
20. Maremmani I., Pacini M., Lubrano S., Giuntoli G., Lovrecic M. (2002): Harm reduction and specific treatments for heroin addiction. Different approaches or levels of intervention?. An illness-centred perspective. Heroin Addict Relat Clin Probl. 4(3): 5-11.
21. Maremmani I., Pacini M., Pani P. P., On Behalf of the ’Basics on Addiction Group’ (2011): Basics on Addiction: a training package for medical practitioners or psychiatrists who treat opioid dependence. Heroin Addict Relat Clin Probl. 13(2): 5-40.
22. Maremmani I., Pacini M., Pani P. P., Parrino M. (2006): Say “Yes” to Methadone and Buprenorphine in Russian Federation. Heroin Addict Relat Clin Probl. 8(2): 5-22.
23. Maremmani I., Pacini M., Pani P. P., Perugi G., Deltito J., Akiskal H. (2007): The mental status of 1090 heroin addicts at entry into treatment: should depression be considered a ’dual diagnosis’? Ann Gen Psychiatry. 6: 31.
24. Maremmani I., Pani P. P. (2013): The Psychopathology of Addiction. Heroin Addict Relat Clin Probl. 15(2): 5-6.
25. Maremmani I., Pani P. P., Mellini A., Pacini M., Marini G., Lovrecic M., Perugi G., Shinderman M. (2007): Alcohol and cocaine use and abuse among opioid addicts engaged in a methadone maintenance treatment program. J Addict Dis. 26(1): 61-70.
26. Maremmani I., Pani P. P., Pacini M., Bizzarri J. V., Trogu E., Maremmani A. G. I., Perugi G., Gerra G., Dell’osso L. (2010): Subtyping Patients with Heroin Addiction at Treatment Entry: Factors Derived fron the SCL-90. Ann Gen Psychiatry. 9(1): 15.
27. Maremmani I., Shinderman M. S. (1999): Alcohol, benzodiazepines and other drugs use in heroin addicts treated with methadone. Polyabuse or undermedication? Heroin Addict Relat Clin Probl. 1(2): 7-13.
28. Mattick R. P., Breen C., Kimber J., Davoli M. (2003): Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev(2): CD002209.
29. Pacini M., Mellini A., Attilia M. L., Ceccanti M., Maremmani I. (2005): Alcohol abuse in heroin addicts: An unfolding metabolic destiny. Heroin Addict Relat Clin Probl. 7(1): 31-38.
30. Pani P. P., Maremmani A. G. I., Trogu E., Ruiz P., Akiskal H. S., Maremmani I. (2013): It’s time to admit the existence of a psychopathology of addiction. Heroin Addict Relat Clin Probl. 15(2): 7-18.
31. Pani P. P., Maremmani I., Trogu E., Gessa G. L., Ruiz P., Akiskal H. S. (2010): Delineating the psychic structure of substance abuse and addictions: Should anxiety, mood and impulse-control dysregulation be included? J Affect Disord. 122: 185-197.
32. Subata E., Gilman M., Alho H., Maremmani I. (2013): Recommendations for measuring treatment outcomes in opioid dependence management: consensus from the GLADD meeting. Heroin Addict Relat Clin Probl. 15(3): 55-60.
33. Ulmer A., Lamy D., Reisinger M., Haraldsen M., Maremmani I., Newman R. (2012): How should Methadone-and Buprenorphine-Treatment be organized and regulated? A comparison of two systems in the context of an Europad-conference in Brussels. Heroin Addict Relat Clin Probl. 14(1): 5-10.